Search Result

Results for "

solid tumour

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (1) Apoptosis (4) Autophagy (1) Caspase (1) CCR (2) CD3 (1) CD47 (2) Complement System (1) DNA Alkylator/Crosslinker (1) Drug Derivative (1) FLAP (1) HDAC (2) Interleukin Related (2) LAG-3 (1) Monocarboxylate Transporter (1) mTOR (1) Opioid Receptor (1) PD-1/PD-L1 (8) Phosphodiesterase (PDE) (1) Ser/Thr Protease (1) SHP1 (1) STING (1) TNF Receptor (3) Toll-like Receptor (TLR) (1) Transmembrane Glycoprotein (3)
By Research Areas:	Cancer (35) Inflammation/Immunology (2) Neurological Disease (1)

By Targets:

Adenosine Receptor (1)

Apoptosis (4)

Autophagy (1)

Caspase (1)

CCR (2)

CD3 (1)

CD47 (2)

Complement System (1)

DNA Alkylator/Crosslinker (1)

Drug Derivative (1)

FLAP (1)

HDAC (2)

Interleukin Related (2)

LAG-3 (1)

Monocarboxylate Transporter (1)

mTOR (1)

Opioid Receptor (1)

PD-1/PD-L1 (8)

Phosphodiesterase (PDE) (1)

Ser/Thr Protease (1)

SHP1 (1)

STING (1)

TNF Receptor (3)

Toll-like Receptor (TLR) (1)

Transmembrane Glycoprotein (3)

By Research Areas:

Cancer (35)

Inflammation/Immunology (2)

Neurological Disease (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99011

Cibisatamab 2 Publications Verification	CD3	Cancer
Cibisatamab, a T cell bispecific antibody, binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells. Cibisatamab triggers T cell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. Cibisatamab can be used for colorectal cancer research .

HY-172320

BMS-986238	PD-1/PD-L1	Cancer
BMS-986238 is an orally active macrocyclic peptide PD-L1 inhibitor. BMS-986238 can be used in the research of tumors such as solid tumors and lymphomas .

HY-150314

MCT-IN-1	Monocarboxylate Transporter	Cancer
MCT-IN-1 (Compound 2) is a potent MCT inhibitor, with IC₅₀ values of 9 nM and 14 nM against MCT1 and MCT4, respectively. MCT-IN-1 can be used in research related to solid tumors .

HY-P99450

Avdoralimab IPH 5401; Anti-C5aR1 mAb	Complement System	Inflammation/Immunology Cancer
Avdoralimab (IPH 5401) is a fully human IgGκ monoclonal antibody that targets the complement C5a receptor 1 (C5aR1) that prevents its binding to C5a. Avdoralimab can be used for complement-driven inflammatory diseases and solid tumours research .

HY-13432

Nanatinostat 2 Publications Verification CHR-3996	HDAC Apoptosis	Cancer
Nanatinostat (CHR-3996) is a potent, class I selective and orally active HDAC inhibitor with IC₅₀s of 3 nM, 4 nM, and 7 nM for HDAC1, HDAC2, and HDAC3, respectively. Nanatinostat has low activity against HDAC5 (IC₅₀ of 200 nM) and HDAC6 (IC₅₀ of 2100 nM). Nanatinostat induces apoptosis in myeloma cells. Nanatinostat has potent anticancer effects, such as myeloma, advanced solid tumours and colorectal cancer .

HY-P99114

Sugemalimab	PD-1/PD-L1	Cancer
Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research .

HY-176761

NSC647889	Apoptosis Autophagy Caspase mTOR	Cancer
NSC647889 is an apoptosis and autophagy inducer. NSC647889 induces apoptosis, inhibits mTOR pathway and abrogates DNA synthesis. NSC647889 triggers LC3-positive vesicle formation, modulates AKT and 4EBP1 phosphorylation and shows heightened caspase-3 activation in multicellular spheroids. NSC647889 can be used for the research of solid cancer tumour, head-neck carcinoma, and colorectal cancer .

HY-139678

SC13	FLAP Opioid Receptor Apoptosis STING	Neurological Disease Cancer
SC13 is an orally active, selective Flap structure-specific endonuclease 1 (FEN1) inhibitor and mu opioid receptor (MOR) activator. SC13 impairs DNA damage repair and induces apoptosis in cancer cells. SC13 activates cGAS-STING signaling, increases chemokine secretion, and promotes CAR-T cell infiltration at solid tumour sites. SC13 can be used for the research of solid tumours and pain .

HY-P991455

PTX-35	TNF Receptor	Cancer
PTX-35 is a human IgG monoclonal antibody (mAb) targeting TNFRSF25. PTX-35 reduces the suppressive activity of regulatory T cells and enhances CD4+ T cell effector responses in a mouse melanoma model. PTX-35 can be used in Islet cell transplant rejection and Solid tumours research. Recommended isotype control: Human IgG1 lambda2, Isotype Control (HY-P990096) .

HY-P991469

AMG-211 MEDI-565	Transmembrane Glycoprotein	Cancer
AMG-211 (MEDI-565)i s a bispecific antibody targeting CD3E and CEACAM5/CEA/CD66e. AMG-211 can be used in Gastrointestinal cancer and Solid tumours research .

HY-139453A

LP-284	DNA Alkylator/Crosslinker	Cancer
LP-284 is a potent DNA alkylating agent that kills solid tumours. LP-284 can be used in the studies of hematologic cancers with compromised DNA repair, such as mantle cell lymphoma (MCL) .

HY-111786

LHC-165	Toll-like Receptor (TLR)	Cancer
LHC-165 is a TLR7 agonist. LHC-165 has potential to used in study of solid tumors .

HY-148954

PBF-999	Adenosine Receptor Phosphodiesterase (PDE)	Cancer
PBF-999 is a phosphodiesterase10A (PDE-10A) and adenosine A2A receptor (A2AR) dual antagonist.

HY-P991348

BAT-1306	PD-1/PD-L1	Cancer
BAT-1306 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. BAT-1306 can be used in Colorectal cancer and Solid tumours research .

HY-P991391

COM902	Transmembrane Glycoprotein	Cancer
COM902 is a human IgG4 monoclonal antibody (mAb) targeting TIGIT. COM902 enhances anti-tumor immune responses. COM902 can be used in Multiple myeloma, Solid tumours and Colorectal cancer research. Recommended isotype control: IgG4-lambda .

HY-P991560

TQB-2928	CD47	Cancer
TQB-2928 is a monoclonal antibody against CD47, which can be used in the study of cancer.

HY-128470

Mitoquidone GR-30921	Drug Derivative	Cancer
Mitoquidone (GR-30921) is is the first member of a group of pentacyclic pyrroloquinones. Mitoquidone shows good activity in a range of experimental solid tumour models. Mitoquidone can be used for the research of anti-cancer .

HY-P991344

AMP-224	PD-1/PD-L1	Cancer
AMP-224 is a fusion protein targeting PD-L2. AMP-224 specifically binds to PD-1 T cells (chronically stimulated/exhausted T cells). AMP-224 can be used in Colorectal cancer and Solid tumours research .

HY-13432A

Nanatinostat TFA CHR-3996 TFA	HDAC Apoptosis	Cancer
Nanatinostat (CHR-3996) TFA is a potent, class I selective and orally active HDAC inhibitor with IC₅₀s of 3 nM, 4 nM, and 7 nM for HDAC1, HDAC2, and HDAC3, respectively. Nanatinostat TFA has low activity against HDAC5 (IC₅₀ of 200 nM) and HDAC6 (IC₅₀ of 2100 nM). Nanatinostat TFA induces apoptosis in myeloma cells. Nanatinostat TFA has potent anticancer effects, such as myeloma, advanced solid tumours and colorectal cancer .

HY-P991438

XmAb-662	Interleukin Related	Cancer
XmAb-662 is a fusion protein targeting IL-12. XmAb-662 can be used in solid tumours research .

HY-P991390

BAT-6021	Transmembrane Glycoprotein	Cancer
BAT-6021 is a human monoclonal antibody (mAb) targeting TIGIT. BAT-6021 can be used in Solid tumours research .

HY-P991605

HLX26	LAG-3	Cancer
HLX26 is a humanised anti-LAG-3 monoclonal antibody. HLX26 has antitumor activity especially advanced solid tumours. HLX26 can be used for lymphoma research .

HY-P991357

STT-001	PD-1/PD-L1	Cancer
STT-001 is a human monoclonal antibody (mAb) targeting B7-H1/PD-L1/CD274. STT-001 can be used in Solid tumours research .

HY-P991367

ES004	CD47	Cancer
ES004 is a human monoclonal antibody (mAb) targeting SIRPα/CD172a. ES004 enhances macrophage phagocytosis and induces potent T cell responses to promote tumor killing. ES004 can be used in Solid tumours research .

HY-P991354

GR-1405	PD-1/PD-L1	Cancer
GR-1405 is a human monoclonal antibody (mAb) targeting B7-H1/PD-L1/CD274. GR-1405 enhances cytotoxic T lymphocyte (CTL)-mediated antitumor immune responses against PD-L1-expressing tumor cells. GR-1405 can be used in Lymphoma and Solid tumours research .

HY-P991349

GNR-051	PD-1/PD-L1	Cancer
GNR-051 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. GNR-051 can be used in Solid tumours research .

HY-P992315

ASP1951 PTZ-522	TNF Receptor	Cancer
ASP1951 (PTZ-522) is a monoclonal antibody that targets GITR and is a GITR agonist. ASP1951 can be used for the research of advanced solid tumours .

HY-P992368

HLX51	TNF Receptor	Cancer
HLX51 is a regulatory T cell inhibitor and OX40/CD134/TNFRSF4 agonist with tumour growth inhibitory activity. HLX51 inhibits regulatory T cell differentiation and activity, relieves tumour microenvironment immunosuppression, enhances effector T cell function. HLX51 competitively binds OX40, activates OX40, promotes immune cell proliferation and T cell killing ability. HLX51 modulates immune cell function to inhibit tumour growth. HLX51 can be used for the research of advanced/metastatic solid tumours and lymphomas .

HY-P991944A

ZL-1218 (FUT8-KO)	CCR	Cancer
ZL-1218 (FUT8-KO) is an anti-CCR8 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody. ZL-1218 (FUT8-KO) can be used for the research of solid tumour .

HY-P991944

ZL-1218	CCR	Cancer
ZL-1218 is a selective humanized IgG1 antibody, targeting CCR8. ZL-1218 induces antibody-dependent cellular cytotoxicity (ADCC), leading to NK cell-mediated depletion of CCR8-expressing regulatory T cells (Tregs). ZL-1218 blocks the binding of the CCR8 ligand CCL1 to CCR8 and reduces Treg recruitment by inhibiting the chemotaxis of CCR8 ⁺ cells. ZL-1218 reduces intratumoral Treg levels in a dose-dependent manner. ZL-1218 exerts enhanced antitumor activity when combined with the anti-PD-1 antibody. ZL-1218 can be used for solid tumour research .

HY-182450

WX-293	Ser/Thr Protease	Cancer
WX-293 is a highly selective urokinase-type plasminogen activator (uPA) inhibitor with a K_i value of 2.4 μM. WX-293 abolishes hypoxia-induced keratinocyte migration and in vitro wound closure. WX-293 can be used in research on hypoxia-mediated skin wounds and solid malignant tumors .

HY-P992434

OSE-279	PD-1/PD-L1 SHP1 Interleukin Related	Cancer
OSE-279 is a high-affinity humanized monoclonal bivalent antibody targeting PD-1, the recommended isotype control is HY-P99003. OSE-279 blocks PD-1 ligand binding, inhibits PDL1-induced SHP1 phosphorylation, restores T cell activation, and promotes reactivation of primary T cell effector functions. OSE-279 binds hFcRn receptor, predicts long half-life, induces CD4 and CD8 T cell proliferation, and promotes interleukin 2 and interferon gamma secretion. OSE-279 can be used for the research of advanced malignancies, colon cancer, hepatocarcinoma, mesothelioma .

Cat. No.	Product Name	Target	Research Area